Drew Deniger

Drew Deniger

Auto-generated profile, based on publicly available information

Drew Deniger

The University of Texas MD Anderson Cancer Center 1 Department of Thoracic/Head & Neck Medical Oncology Houston, Texas

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PMParisa Malekzadeh
Parisa Malekzadeh
APAnna Pasetto
Anna Pasetto
PRPaul F. Robbins
Paul F. Robbins
MPMaria R. Parkhurst
Maria R. Parkhurst
BPBiman C. Paria
Biman C. Paria
DDDrew C. Deniger
Drew C. Deniger

23 June 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
SKSanghyun P. Kim
Sanghyun P. Kim
NVNolan R. Vale
Nolan R. Vale
NZNikolaos Zacharakis
Nikolaos Zacharakis
SKSri Krishna
Sri Krishna
ZYZhiya Yu
Zhiya Yu
SRSteven A. Rosenberg
Steven A. Rosenberg
Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT targeting neoantigens, we focused on TP53 mutations commonly shared across different cancer types. We performed whole-exome sequencing on 163 patients with metastatic solid cancers, identified 78 who had TP53 missense mutations, and through immunologic screening, identified 21 unique T-cell reactivities. Here, we report a library of 39 T-cell receptors (TCR) targeting TP53 mutations shared among 7.3% of patients with solid tumors. These TCRs recognized tumor cells in a TP53 mutation- and human leucocyte antigen (HLA)-specific manner in vitro and in vivo. Twelve patients with chemorefractory epithelial cancers were treated with ex vivo–expanded autologous tumor-infiltrating lymphocytes (TIL) that were naturally reactive against TP53 mutations. However, limited clinical responses (2 partial responses among 12 patients) were seen. These infusions contained low frequencies of mutant p53–reactive TILs that had exhausted phenotypes and showed poor persistence. We also treated one patient who had chemorefractory breast cancer with ACT comprising autologous peripheral blood lymphocytes transduced with an allogeneic HLA-A*02–restricted TCR specific for p53R175H. The infused cells exhibited an improved immunophenotype and prolonged persistence compared with TIL ACT and the patient experienced an objective tumor regression (-55%) that lasted 6 months. Collectively, these proof-of-concept data suggest that the library of TCRs targeting shared p53 neoantigens should be further evaluated for the treatment of patients with advanced human cancers. See related Spotlight by Klebanoff, p. 919

4 January 2019 in Science Immunology
Verified
Journal Article
Closed access
PDF file
MAMojgan Ahmadzadeh
Mojgan Ahmadzadeh
APAnna Pasetto
Anna Pasetto
LJLi Jia
Li Jia
DDDrew C. Deniger
Drew C. Deniger
SSSanja Stevanović
Sanja Stevanović
SRSteven A. Rosenberg
Steven A. Rosenberg
Intratumoral T reg cells are tumor/neoantigen reactive.

25 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
GCGal Cafri
Gal Cafri
RYRami Yossef
Rami Yossef
APAnna Pasetto
Anna Pasetto
DDDrew C. Deniger
Drew C. Deniger
YLYong-Chen Lu
Yong-Chen Lu
SRSteven A. Rosenberg
Steven A. Rosenberg
T cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor infiltrating lymphocytes, but whether such cells can be detected in the peripheral blood of patients with the common metastatic epithelial cancer patients is unknown. Using a highly sensitive in vitro stimulation and cell enrichment of peripheral memory T cells from six metastatic cancer patients, we identified and isolated CD4+, and CD8+ memory T cells targeting the mutated KRASG12D and KRASG12V variants, respectively, in three patients. In an additional two metastatic colon cancer patients, we detected CD8+ neoantigen-specific cells targeting the mutated SMAD5 and MUC4 proteins. Therefore, memory T cells targeting unique as well as shared somatic mutations can be detected in the peripheral blood of epithelial cancer patients and can potentially be used for the development of effective personalized T cell-based cancer immunotherapy across multiple patients.

15 January 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DDDrew C. Deniger
Drew C. Deniger
MKMei Li M. Kwong
Mei Li M. Kwong
APAnna Pasetto
Anna Pasetto
MDMark E. Dudley
Mark E. Dudley
JWJohn R. Wunderlich
John R. Wunderlich
SRSteven A. Rosenberg
Steven A. Rosenberg
Purpose: This pilot feasibility clinical trial evaluated the coadministration of vemurafenib, a small-molecule antagonist of BRAFV600 mutations, and tumor-infiltrating lymphocytes (TIL) for the treatment of metastatic melanoma. Experimental Design: A metastatic tumor was resected for growth of TILs, and patients were treated with vemurafenib for 2 weeks, followed by resection of a second lesion. Patients then received a nonmyeloablative preconditioning regimen, infusion of autologous TILs, and high-dose interleukin-2 administration. Vemurafenib was restarted at the time of TIL infusion and was continued for 2 years or until disease progression. Clinical responses were evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Metastases resected prior to and after 2 weeks of vemurafenib were compared using TCRB deep sequencing, immunohistochemistry, proliferation, and recognition of autologous tumor. Results: The treatment was well tolerated and had a safety profile similar to that of TIL or vemurafenib alone. Seven of 11 patients (64%) experienced an objective clinical response, and 2 patients (18%) had a complete response for 3 years (one response is ongoing at 46 months). Proliferation and viability of infusion bag TILs and peripheral blood T cells were inhibited in vitro by research-grade vemurafenib (PLX4032) when approaching the maximum serum concentration of vemurafenib. TCRB repertoire (clonotypes numbers, clonality, and frequency) did not significantly change between pre- and post-vemurafenib lesions. Recognition of autologous tumor by T cells was similar between TILs grown from pre- and post-vemurafenib metastases. Conclusions: Coadministration of vemurafenib and TILs was safe and feasible and generated objective clinical responses in this small pilot clinical trial. Clin Cancer Res; 23(2); 351–62. ©2016 AACR. See related commentary by Cogdill et al., p. 327

19 March 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
EBEmily Bontekoe
Emily Bontekoe
MZMinying Zhang
Minying Zhang
PJPeixin Jiang
Peixin Jiang
AMAmanda Montoya
Amanda Montoya
YSYulia Shulga
Yulia Shulga
Alexandre ReubenAlexandre Reuben
Alexandre Reuben
FOXM1 is highly expressed in various cancer types and considered a key driver of cancer progression. Accordingly, we evaluated the immunogenicity of FOXM1 and investigated the feasibility of targeting this transcription factor using T-cell receptor (TCR) engineering. We identified epitopes derived from FOXM1 which were immunogenic on HLA-A*02:01, HLA-A*24:02, and HLA-A*23:01, endogenously processed and presented, and resulted in T-cell activation and cytotoxic T-cell responses. Following the generation of TCR-T cells, sensitivity and specificity were confirmed by peptide dose–response and X-scan, respectively. Most importantly, adoptive transfer of TCR-engineered T cells led to a significant reduction in tumor growth, as well as significantly prolonged survival in a tumor-bearing immunocompromised murine model. Our studies confirm the immunogenicity of FOXM1 and feasibility of targeting this antigen using TCR engineering.